JP2019531356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531356A5 JP2019531356A5 JP2019541901A JP2019541901A JP2019531356A5 JP 2019531356 A5 JP2019531356 A5 JP 2019531356A5 JP 2019541901 A JP2019541901 A JP 2019541901A JP 2019541901 A JP2019541901 A JP 2019541901A JP 2019531356 A5 JP2019531356 A5 JP 2019531356A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- organ transplant
- manufacture
- formula
- pharmaceutical compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000056 organ Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 229940122355 Insulin sensitizer Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408459P | 2016-10-14 | 2016-10-14 | |
| US62/408,459 | 2016-10-14 | ||
| US201762570973P | 2017-10-11 | 2017-10-11 | |
| US62/570,973 | 2017-10-11 | ||
| PCT/IB2017/056417 WO2018069907A1 (en) | 2016-10-14 | 2017-10-16 | Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531356A JP2019531356A (ja) | 2019-10-31 |
| JP2019531356A5 true JP2019531356A5 (enExample) | 2020-11-12 |
| JP6923659B2 JP6923659B2 (ja) | 2021-08-25 |
Family
ID=60382484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541901A Active JP6923659B2 (ja) | 2016-10-14 | 2017-10-16 | 多能性抗炎症及び代謝調節剤を用いた炎症関連症状の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10537537B2 (enExample) |
| EP (2) | EP3525780B1 (enExample) |
| JP (1) | JP6923659B2 (enExample) |
| CN (1) | CN110325182B (enExample) |
| AU (1) | AU2017342167B2 (enExample) |
| CL (1) | CL2019001014A1 (enExample) |
| ES (2) | ES2886122T3 (enExample) |
| MX (1) | MX394475B (enExample) |
| WO (1) | WO2018069907A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190080A1 (ar) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
| US11400066B2 (en) | 2016-10-14 | 2022-08-02 | Institut Pasteur De Montevideo | Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators |
| MX394475B (es) | 2016-10-14 | 2025-03-24 | Inst Pasteur De Montevideo | Métodos para el tratamiento de las condiciones relacionadas con la inflamación utilizando moduladores antiinflamatorios y metábolicos pluripotentes. |
| AU2017444990B2 (en) * | 2017-12-27 | 2022-12-01 | Carlos Batthyány | Nitroalkene non steroidal anti-inflammatory drugs (NA-NSAIDs) and methods of treating inflammation related conditions |
| WO2019145899A1 (en) * | 2018-01-24 | 2019-08-01 | Institut Pasteur De Montevideo | Methods for treating heart transplant rejection |
| AU2019344692B2 (en) * | 2018-09-20 | 2025-07-03 | Carlos Batthyány | Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5113140B2 (enExample) * | 1972-01-13 | 1976-04-26 | ||
| JPS5113140A (en) | 1974-07-23 | 1976-02-02 | Sankyo Alu Ind | Kinzokuseitoshojino nakazan |
| ES2136581B1 (es) * | 1998-05-27 | 2000-09-16 | Uriach & Cia Sa J | Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb. |
| WO2005037323A2 (en) * | 2003-10-10 | 2005-04-28 | University Of Louisville Research Foundation, Inc. | Use of gro to treat or prevent inflammation |
| US20060247263A1 (en) * | 2005-04-19 | 2006-11-02 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US8933255B2 (en) * | 2008-12-31 | 2015-01-13 | Nitromega Corp. | Nutraceuticals containing nitro fatty acids |
| AU2013257717A1 (en) | 2012-05-10 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2015073527A1 (en) | 2013-11-12 | 2015-05-21 | Complexa, Inc. | Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions |
| US11400066B2 (en) | 2016-10-14 | 2022-08-02 | Institut Pasteur De Montevideo | Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators |
| MX394475B (es) | 2016-10-14 | 2025-03-24 | Inst Pasteur De Montevideo | Métodos para el tratamiento de las condiciones relacionadas con la inflamación utilizando moduladores antiinflamatorios y metábolicos pluripotentes. |
| WO2019145899A1 (en) * | 2018-01-24 | 2019-08-01 | Institut Pasteur De Montevideo | Methods for treating heart transplant rejection |
| AU2019344692B2 (en) | 2018-09-20 | 2025-07-03 | Carlos Batthyány | Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators |
-
2017
- 2017-10-16 MX MX2019004402A patent/MX394475B/es unknown
- 2017-10-16 AU AU2017342167A patent/AU2017342167B2/en active Active
- 2017-10-16 CN CN201780077323.2A patent/CN110325182B/zh active Active
- 2017-10-16 WO PCT/IB2017/056417 patent/WO2018069907A1/en not_active Ceased
- 2017-10-16 US US15/784,685 patent/US10537537B2/en active Active
- 2017-10-16 JP JP2019541901A patent/JP6923659B2/ja active Active
- 2017-10-16 EP EP17800605.2A patent/EP3525780B1/en active Active
- 2017-10-16 ES ES17800605T patent/ES2886122T3/es active Active
- 2017-10-16 EP EP21170218.8A patent/EP3878456B1/en active Active
- 2017-10-16 ES ES21170218T patent/ES2945822T3/es active Active
-
2019
- 2019-04-13 CL CL2019001014A patent/CL2019001014A1/es unknown
-
2022
- 2022-06-06 US US17/833,315 patent/US12280029B2/en active Active
-
2025
- 2025-04-10 US US19/175,353 patent/US20250352501A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531356A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2017504611A5 (enExample) | ||
| RU2011108026A (ru) | Комбинированная терапия туберкулеза | |
| JP2020097577A5 (enExample) | ||
| JP2011057693A5 (enExample) | ||
| JP2017518334A5 (enExample) | ||
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| JP2016532667A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2018048154A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| JP2017524735A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| JP2015078230A5 (enExample) | ||
| JP2014507446A5 (enExample) | ||
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| JP2017508817A5 (enExample) | ||
| IL273188B2 (en) | Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor | |
| JP2016537338A5 (enExample) | ||
| JP2013507442A5 (enExample) | ||
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| MX392132B (es) | DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mG1uR2, COMPOSICIONES Y SU USO. |